Alumis (ALMS) Projected to Post Earnings on Wednesday

Alumis (NASDAQ:ALMS) is expected to be posting its Q4 2025 results before the market opens on Wednesday, March 18th. Analysts expect Alumis to post earnings of ($0.90) per share and revenue of $2.75 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 26, 2026 at 4:00 PM ET.

Alumis Stock Down 0.9%

Shares of Alumis stock opened at $24.81 on Monday. Alumis has a 52 week low of $2.76 and a 52 week high of $30.60. The firm’s 50 day moving average is $25.47 and its two-hundred day moving average is $13.11. The firm has a market capitalization of $2.59 billion, a P/E ratio of -6.13 and a beta of -2.16.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Alumis in a report on Monday, December 29th. HC Wainwright reissued a “buy” rating and issued a $40.00 price target (up from $20.00) on shares of Alumis in a research report on Friday, January 9th. Citigroup restated an “outperform” rating on shares of Alumis in a research note on Tuesday, January 6th. Wells Fargo & Company raised their price objective on Alumis from $17.00 to $39.00 and gave the stock an “overweight” rating in a report on Tuesday, January 6th. Finally, Guggenheim lifted their target price on Alumis from $18.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Alumis currently has an average rating of “Moderate Buy” and an average price target of $39.00.

Insider Buying and Selling at Alumis

In other Alumis news, Director James B. Tananbaum purchased 411,764 shares of Alumis stock in a transaction that occurred on Thursday, January 8th. The stock was purchased at an average price of $17.00 per share, for a total transaction of $6,999,988.00. Following the transaction, the director directly owned 5,702,536 shares in the company, valued at $96,943,112. This trade represents a 7.78% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Srinivas Akkaraju purchased 588,235 shares of the firm’s stock in a transaction that occurred on Friday, January 9th. The shares were acquired at an average price of $17.00 per share, with a total value of $9,999,995.00. Following the purchase, the director owned 1,853,488 shares in the company, valued at $31,509,296. This trade represents a 46.49% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders acquired 1,823,527 shares of company stock valued at $30,999,959. Insiders own 40.70% of the company’s stock.

Institutional Investors Weigh In On Alumis

Hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. grew its holdings in shares of Alumis by 320.9% during the third quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company’s stock worth $26,000 after buying an additional 4,894 shares during the last quarter. New York State Common Retirement Fund raised its stake in Alumis by 173.7% during the 2nd quarter. New York State Common Retirement Fund now owns 11,767 shares of the company’s stock valued at $35,000 after acquiring an additional 7,467 shares during the last quarter. BNP Paribas Financial Markets raised its stake in Alumis by 104.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,770 shares of the company’s stock valued at $47,000 after acquiring an additional 6,027 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new stake in Alumis during the 2nd quarter worth approximately $56,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Alumis by 64.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company’s stock worth $77,000 after acquiring an additional 4,926 shares during the period.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.